Are you Dr. Rich?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 28 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
4102 N Roxboro St
Durham, NC 27704Phone+1 919-595-2000Fax+1 919-595-2190
Summary
- Dr. Cadmus Rich, MD is an ophthalmologist in Durham, North Carolina. He is currently licensed to practice medicine in North Carolina.
Education & Training
University of North Carolina HospitalsResidency, Ophthalmology, 1997 - 2000
Carilion Clinic-Virginia Tech Carilion School of MedicineInternship, Transitional Year, 1995 - 1996
University of North Carolina at Chapel Hill School of MedicineClass of 1995
Certifications & Licensure
NC State Medical License 1996 - 2025
Awards, Honors, & Recognition
- Fellow (FAAO) American Academy of Ophthalmology
Publications & Presentations
PubMed
- 33 citationsA Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of 2 and 4 Weeks of Twice-Daily Ocular Trabodenoson in Adults with Ocular ...Jonathan S. Myers, Kenneth N Sall, Harvey Dubiner, Natanya Slomowitz, Mcvicar William K
Journal of Ocular Pharmacology and Therapeutics. 2016-10-01 - 7 citationsTopical Trabodenoson Is Neuroprotective in a Rodent Model of Anterior Ischemic Optic Neuropathy (rNAION).Yan Guo, Zara Mehrabian, Mary A. Johnson, David S Albers, Cadmus C Rich
Translational Vision Science & Technology. 2019-11-01 - 16 citationsA Randomized Phase 1 Dose Escalation Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Trabodenoson in Healthy Adult Volunteers.Alan M. Laties, Cadmus C Rich, Randall Stoltz, Vernon Humbert, Chaim Brickman
Journal of Ocular Pharmacology and Therapeutics. 2016-10-01
Press Mentions
Aura Biosciences Announces Updated Phase 1b/2 Clinical Data for AU-011 Presented at the American Academy of Ophthalmology 2019 Annual MeetingFebruary 24th, 2020
SUBSPECIALTY NEWS: Gene Therapy Data from AAO, FDA Approval of Beovu, and MoreNovember 1st, 2019- Aura Biosciences Announces Successful Outcome of End of Phase 2 Meeting with FDA ForJanuary 4th, 2019
- Join now to see all
Professional Memberships
- Fellow
